"Things will taste different and eating enough nutrients can already be a challenge on these drugs," said White
This is significant, it means a planned 1mg dose is effectively delivering 0.75mg
Many individuals begin experiencing reduced hunger, improved portion control, and fewer cravings as their body adjusts to the treatment
Retatrutide solves this problem through its concurrent GLP-1 activation, which enhances insulin secretion and suppresses inappropriate glucagon release from the pancreas
The 12 mg dose in TRIUMPH-4 led to a 28.7% loss over 68 weeks, while tirzepatide in the SURMOUNT-1 trial produced approximately 22.5% loss over 72 weeks
Agents that agonize glucagon-like peptide 1 receptors, including those that co-agonize other anorexigenic hormone receptors, lead to substantial weight loss and benefits in people with varying obesity-related complications, with further trials underway